IL17A and inflammatory bowel disease: Here, we analyzed the impact of ustekinumab therapy on the presence of CD3+CD4+IL-17+ and CD3+CD4+TNF-α+ T cells in patients with IBD and their response to specific intestinal commensal bacteria common in the Czech population.